🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Denmark / NCT06037096
Recruiting Not applicable

Implementation of a Structured Post-pulmonary Embolism Follow-up Model

NCT06037096 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2022-03-15
Last updated
2025-06-13

Condition(s) studied

Pulmonary Embolism

Investigational drug(s) / intervention(s)

Attend-PE model

Attend-PE model: A pulmonary embolism follow-up care model consisting of structured elements for follow-up after discharge from hospital.

Study summary

Venous thromboembolism (VTE), clinically presenting as deep vein thrombosis or pulmonary embolism (PE) is the third most frequent cardiovascular disease and is associated with substantial short- and long-term morbidity and mortality and high costs of care. In addition negative physical and mental complications following VTE are common. However in terms of PE, there are no structured follow-up programs in Denmark and there is considerable variation in practice patterns of post-PE management both within and between countries.

This project aims to develop, test and implement a structured follow-up care model for patients with PE (The Attend-PE model). This project is a pre-post intervention study and will estimate the effectiveness of implementing the structured follow-up care model on a national level.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * adult patients (≥18 years) * CT-verified diagnosis of PE Exclusion Criteria: * patients who are not living in Denmark on the extraction date * patients with a active cancer

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Aalborg University Hospital Aalborg Denmark Recruiting

More Aalborg University Hospital trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06037096 on ClinicalTrials.gov ↗ ← All trials in Denmark